|
IL314915B1
(en)
|
2017-01-23 |
2026-02-01 |
Regeneron Pharma |
Variants of 17-beta-hydroxysteroid dehydrogenase and their uses
|
|
KR20190139869A
(ko)
|
2017-04-11 |
2019-12-18 |
리제너론 파마슈티칼스 인코포레이티드 |
하이드록시스테로이드 (17-베타) 탈수소효소(hsd17b) 패밀리의 구성원의 조절인자의 활성도를 스크리닝하기 위한 검정
|
|
US11866726B2
(en)
|
2017-07-14 |
2024-01-09 |
Editas Medicine, Inc. |
Systems and methods for targeted integration and genome editing and detection thereof using integrated priming sites
|
|
WO2019028032A1
(en)
|
2017-07-31 |
2019-02-07 |
Regeneron Pharmaceuticals, Inc. |
EMBRYONIC STEM CELLS OF TRANSGENIC MOUSE CASES AND MICE AND USES THEREOF
|
|
CN111182790A
(zh)
|
2017-07-31 |
2020-05-19 |
瑞泽恩制药公司 |
Crispr报告体非人类动物及其用途
|
|
MX394999B
(es)
|
2017-09-29 |
2025-03-24 |
Regeneron Pharma |
Animales no humanos que comprenden un locus ttr humanizado y metodos de uso
|
|
US10961583B2
(en)
|
2017-10-11 |
2021-03-30 |
Regeneron Phramaceuticals, Inc. |
Inhibition of HSD17B13 in the treatment of liver disease in patients expressing the PNPLA3 I148M variation
|
|
CN111885915B
(zh)
|
2018-03-19 |
2023-04-28 |
瑞泽恩制药公司 |
使用crispr/cas系统对动物进行转录调制
|
|
JP7507093B2
(ja)
|
2018-03-21 |
2024-06-27 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
１７β－水酸化ステロイド脱水素酵素１３型（ＨＳＤ１７Ｂ１３）ｉＲＮＡ組成物およびその使用方法
|
|
EP3823633A4
(en)
|
2018-06-29 |
2023-05-03 |
Editas Medicine, Inc. |
SYNTHETIC LEAD MOLECULES, COMPOSITIONS AND METHODS RELATED THERETO
|
|
JP7578590B2
(ja)
|
2018-10-18 |
2024-11-06 |
インテリア セラピューティクス，インコーポレーテッド |
第ｉｘ因子を発現するための組成物及び方法
|
|
EP3946598A1
(en)
*
|
2019-03-28 |
2022-02-09 |
Intellia Therapeutics, Inc. |
Compositions and methods comprising a ttr guide rna and a polynucleotide encoding an rna-guided dna binding agent
|
|
US11891618B2
(en)
|
2019-06-04 |
2024-02-06 |
Regeneron Pharmaceuticals, Inc. |
Mouse comprising a humanized TTR locus with a beta-slip mutation and methods of use
|
|
US11622547B2
(en)
|
2019-06-07 |
2023-04-11 |
Regeneran Pharmaceuticals, Inc. |
Genetically modified mouse that expresses human albumin
|
|
US11845957B2
(en)
|
2019-06-14 |
2023-12-19 |
Regeneron Pharmaceuticals, Inc. |
Models of tauopathy
|
|
WO2021026318A2
(en)
*
|
2019-08-06 |
2021-02-11 |
The Penn State Research Foundation |
Engineered crispr/cas9 systems for simultaneous long-term regulation of multiple targets
|
|
US12521451B2
(en)
|
2019-11-08 |
2026-01-13 |
Regeneron Pharmaceuticals, Inc. |
CRISPR and AAV strategies for x-linked juvenile retinoschisis therapy
|
|
EP4438729A3
(en)
*
|
2019-12-09 |
2025-03-26 |
Caribou Biosciences, Inc. |
Crispr abasic restricted nucleotides and crispr accuracy via analogs
|
|
MX2022006950A
(es)
*
|
2019-12-11 |
2022-11-07 |
Intellia Therapeutics Inc |
Arn guía modificados para edición de genes.
|
|
JP2023512758A
(ja)
|
2020-02-07 |
2023-03-29 |
インテリア セラピューティクス，インコーポレイテッド |
カリクレイン（ｋｌｋｂ１）遺伝子編集のための組成物および方法
|
|
GB2632565B
(en)
*
|
2020-04-09 |
2025-06-04 |
Verve Therapeutics Inc |
Base editing of PCSK9 and methods of using same for treatment of disease
|
|
WO2021231606A2
(en)
*
|
2020-05-12 |
2021-11-18 |
University Of Massachusetts |
Modified guide rnas for crispr genome editing
|
|
CA3204997A1
(en)
|
2020-12-11 |
2022-06-16 |
Intellia Therapeutics, Inc. |
Compositions and methods for reducing mhc class ii in a cell
|
|
CR20230305A
(es)
|
2020-12-11 |
2023-11-10 |
Intellia Therapeutics Inc |
Polinucleótidos, composiciones y métodos para la edición del genoma que implican desaminación
|
|
AU2021409732A1
(en)
|
2020-12-23 |
2023-07-20 |
Intellia Therapeutics, Inc. |
Compositions and methods for reducing hla-a in a cell
|
|
TW202242101A
(zh)
|
2020-12-23 |
2022-11-01 |
美商英特利亞醫療公司 |
用於細胞中基因修飾ciita之組合物及方法
|
|
JP2024505672A
(ja)
|
2021-02-08 |
2024-02-07 |
インテリア セラピューティクス，インコーポレイテッド |
免疫療法のためのナチュラルキラー細胞受容体２ｂ４組成物及び方法
|
|
JP2024506016A
(ja)
|
2021-02-08 |
2024-02-08 |
インテリア セラピューティクス，インコーポレイテッド |
免疫療法のためのｔ細胞免疫グロブリン及びムチンドメイン３（ｔｉｍ３）組成物及び方法
|
|
WO2022170194A2
(en)
|
2021-02-08 |
2022-08-11 |
Intellia Therapeutics, Inc. |
Lymphocyte activation gene 3 (lag3) compositions and methods for immunotherapy
|
|
EP4298212A4
(en)
*
|
2021-02-25 |
2026-04-15 |
Celyntra Therapeutics Sa |
Compositions and methods for targeting, editing, or modifying genes
|
|
EP4392060A1
(en)
|
2021-08-24 |
2024-07-03 |
Intellia Therapeutics, Inc. |
Programmed cell death protein 1 (pd1) compositions and methods for cell-based therapy
|
|
EP4426338A2
(en)
|
2021-11-03 |
2024-09-11 |
Intellia Therapeutics, Inc. |
Cd38 compositions and methods for immunotherapy
|
|
WO2023081687A1
(en)
*
|
2021-11-03 |
2023-05-11 |
Intellia Therapeutics, Inc. |
Modified guide rnas for gene editing
|
|
CN118632622A
(zh)
|
2021-12-08 |
2024-09-10 |
瑞泽恩制药公司 |
突变型肌纤蛋白疾病模型及其用途
|
|
WO2023185697A2
(en)
*
|
2022-03-29 |
2023-10-05 |
Accuredit Therapeutics (Suzhou) Co., Ltd. |
Compositions and methods for treatment of transthyretin amyloidosis
|
|
CN114574598B
(zh)
*
|
2022-04-02 |
2023-08-08 |
中国农业科学院北京畜牧兽医研究所 |
鉴定或辅助鉴定猪5/6肋眼肌面积的方法
|
|
CN119923466A
(zh)
*
|
2022-06-15 |
2025-05-02 |
比姆医疗股份有限公司 |
用于减少补体激活的组合物和方法
|
|
CN119384498A
(zh)
|
2022-06-16 |
2025-01-28 |
因特利亚治疗公司 |
用于对细胞进行遗传修饰的方法和组合物
|
|
EP4540389A2
(en)
|
2022-06-16 |
2025-04-23 |
Intellia Therapeutics, Inc. |
Compositions and methods for reducing mhc class i in a cell
|
|
CN119585419A
(zh)
|
2022-06-29 |
2025-03-07 |
因特利亚治疗公司 |
工程化t细胞
|
|
TW202417017A
(zh)
*
|
2022-06-30 |
2024-05-01 |
香港商正基基因科技有限公司 |
具有化學修飾的導引rna
|
|
WO2024137766A2
(en)
|
2022-12-21 |
2024-06-27 |
Intellia Therapeutics, Inc. |
Compositions and methods for proprotein convertase subtilisin kexin 9 (pcsk9) editing
|
|
WO2024138115A1
(en)
|
2022-12-23 |
2024-06-27 |
Intellia Theraperutics, Inc. |
Systems and methods for genomic editing
|
|
WO2024186890A1
(en)
|
2023-03-06 |
2024-09-12 |
Intellia Therapeutics, Inc. |
Compositions and methods for hepatitis b virus (hbv) genome editing
|
|
EP4677067A1
(en)
|
2023-03-07 |
2026-01-14 |
Intellia Therapeutics, Inc. |
Cish compositions and methods for immunotherapy
|
|
IL324634A
(en)
|
2023-05-15 |
2026-01-01 |
Nchroma Bio Inc |
Compositions and methods for epigenetic regulation of hbv gene expression
|
|
WO2025007951A1
(zh)
*
|
2023-07-06 |
2025-01-09 |
上海交通大学 |
一种靶向ttr的sacas9 sgrna及其修饰方式
|
|
WO2025038637A1
(en)
|
2023-08-14 |
2025-02-20 |
Intellia Therapeutics, Inc. |
Compositions and methods for genetically modifying transforming growth factor beta receptor type 2 (tgfβr2)
|
|
TW202515994A
(zh)
|
2023-08-14 |
2025-04-16 |
美商英特利亞醫療公司 |
用於對ｃｄ７０進行基因修飾之組合物及方法
|
|
TW202521564A
(zh)
|
2023-08-14 |
2025-06-01 |
美商英特利亞醫療公司 |
用於基於細胞之療法的ｃｄ７０ ｃａｒ－ｔ組合物及方法
|
|
WO2025059328A1
(en)
*
|
2023-09-14 |
2025-03-20 |
Empirico Inc. |
Modified oligonucleotides
|
|
TW202540417A
(zh)
|
2023-11-10 |
2025-10-16 |
美商英特利亞醫療公司 |
用於基因體編輯之組合物、方法及系統
|
|
WO2025128871A2
(en)
|
2023-12-13 |
2025-06-19 |
Renagade Therapeutics Management Inc. |
Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
|
|
WO2025137439A2
(en)
|
2023-12-20 |
2025-06-26 |
Intellia Therapeutics, Inc. |
Engineered t cells
|
|
WO2025137301A1
(en)
|
2023-12-20 |
2025-06-26 |
Intellia Therapeutics, Inc. |
Methods for rapid engineering of cells
|
|
WO2025184520A1
(en)
|
2024-02-29 |
2025-09-04 |
Intellia Therapeutics, Inc. |
Compositions and methods for angiopoietin like 3 (angptl3) editing
|
|
CN117925623B
(zh)
*
|
2024-03-20 |
2024-06-07 |
北京引正基因科技有限公司 |
用于hao1基因编辑和治疗ph1的组合物
|
|
WO2025240946A1
(en)
|
2024-05-17 |
2025-11-20 |
Intellia Therapeutics, Inc. |
Lipid nanoparticles and lipid nanoparticle compositions
|
|
WO2025255308A1
(en)
|
2024-06-07 |
2025-12-11 |
Intellia Therapeutics, Inc. |
Cd8 co-receptor chimeric polypeptides in tcr cell therapy
|